Get the Stockscreener App
21.67
1.93%
0.44
Cidara Therapeutics Inc stock is traded at $21.67, with a volume of 101.49K.
It is up +1.93% in the last 24 hours and down -19.85% over the past month.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
See More
Previous Close:
$21.23
Open:
$21.38
24h Volume:
101.49K
Relative Volume:
1.17
Market Cap:
$232.37M
Revenue:
$56.54M
Net Income/Loss:
$-30.70M
P/E Ratio:
-55.56
EPS:
-0.39
Net Cash Flow:
$-31.05M
1W Performance:
+16.50%
1M Performance:
-19.85%
6M Performance:
+91.67%
1Y Performance:
+65.14%
1-Day Range:
$21.06
$21.94
1-Week Range:
$18.04
$21.94
52-Week Range:
$10.00
$28.42
Cidara Therapeutics Inc Stock (CDTX) Company Profile
Name
Cidara Therapeutics Inc
Sector
Industry
Phone
858-752-6170
Address
6310 NANCY RIDGE DRIVE, SAN DIEGO, CA
Compare CDTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CDTX
Cidara Therapeutics Inc
|
21.57 | 232.37M | 56.54M | -30.70M | -31.05M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.30 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.62 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
651.00 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.97 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.75 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cidara Therapeutics Inc Stock (CDTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-25 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-13-24 | Initiated | RBC Capital Mkts | Outperform |
| Nov-08-24 | Initiated | Guggenheim | Buy |
| Aug-14-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-03-21 | Resumed | H.C. Wainwright | Buy |
| Sep-22-21 | Upgrade | WBB Securities | Buy → Strong Buy |
| Mar-04-21 | Initiated | Aegis Capital | Buy |
| Sep-04-19 | Upgrade | Wedbush | Neutral → Outperform |
| Jul-26-18 | Initiated | Citigroup | Buy |
| Apr-21-17 | Initiated | Raymond James | Strong Buy |
| Apr-17-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-12-17 | Initiated | Ladenburg Thalmann | Buy |
| Apr-11-17 | Resumed | Wedbush | Outperform |
| Feb-22-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-17 | Upgrade | WBB Securities | Sell → Hold |
| Dec-21-16 | Resumed | Leerink Partners | Outperform |
| Dec-19-16 | Initiated | H.C. Wainwright | Buy |
| Sep-23-16 | Downgrade | WBB Securities | Hold → Sell |
| Oct-09-15 | Upgrade | WBB Securities | Sell → Hold |
| May-11-15 | Initiated | Jefferies | Buy |
| May-11-15 | Initiated | Leerink Partners | Outperform |
| May-11-15 | Initiated | Needham | Buy |
| May-11-15 | Initiated | Wedbush | Outperform |
| Apr-23-15 | Initiated | WBB Securities | Sell |
View All
Cidara Therapeutics Inc Stock (CDTX) Latest News
Cidara Therapeutics (NASDAQ:CDTX) Stock Rating Upgraded by Cantor Fitzgerald - Defense World
Cidara Therapeutics (NASDAQ:CDTX) Raised to Strong-Buy at Cantor Fitzgerald - MarketBeat
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Short Interest Up 113.6% in January - MarketBeat
Cidara Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire
Inside Cidara's Next Move: CEO Jeffrey Stein Takes Center Stage at Elite Biotech Conference - StockTitan
Long Term Trading Analysis for (CDTX) - Stock Traders Daily
Cantor Fitzgerald raises Cidara stock to Overweight - MSN
Cidara Therapeutics’ (CDTX) “Overweight” Rating Reaffirmed at Cantor Fitzgerald - Defense World
Cantor Fitzgerald raises Cidara stock to Overweight By Investing.com - Investing.com Canada
Cidara Therapeutics (NASDAQ:CDTX) Receives "Overweight" Rating from Cantor Fitzgerald - MarketBeat
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Cidara Therapeutics (NASDAQ:CDTX) Share Price Passes Above 50 Day Moving AverageWhat's Next? - MarketBeat
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives $32.20 Consensus Price Target from Analysts - MarketBeat
Contrasting Cidara Therapeutics (NASDAQ:CDTX) and Kodiak Sciences (NASDAQ:KOD) - Defense World
Here’s Why Cidara Therapeutics, Inc. (CDTX) Is Skyrocketing - MSN
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Short Interest Update - MarketBeat
Why These 24 Stocks Are Skyrocketing - Insider Monkey
Geode Capital Management LLC Buys 9,771 Shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX) - Defense World
(CDTX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Cidara Therapeutics (NASDAQ:CDTX) Shares Cross Above 50 Day Moving AverageTime to Sell? - MarketBeat
Cidara Therapeutics announces board changes, CMO separation - Investing.com
Cidara Therapeutics Announces Leadership Changes and Appointments - MSN
Cidara Therapeutics, Inc. Announces Management Changes - Marketscreener.com
Aspergillosis Market Expected to rise, 2034 | Regeneron, Pulmocide, Astellas Pharma, Cipla, Pulmatrix, F2G, Cellix Bio, SCYNEXIS, TFF, Matinas BioPharma, Amplyx Pharmaceuticals, Cidara Therapeutics, I - The Globe and Mail
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives $32.20 Average PT from Analysts - Defense World
Cidara Therapeutics stock soars to 52-week high of $24.99 By Investing.com - Investing.com Nigeria
Cidara Therapeutics stock soars to 52-week high of $24.99 - Investing.com
(CDTX) Proactive Strategies - Stock Traders Daily
Analysts Set Cidara Therapeutics, Inc. (NASDAQ:CDTX) PT at $32.20 - MarketBeat
Influenza A Infections Market Overview: Size, Share, and Future - openPR
Cidara Therapeutics files to sell 7.04M shares of common stocks by selling shareholders - MSN
Cidara Therapeutics (CDTX) Just Flashed Golden Cross Signal: Do You Buy? - MSN
Cidara Therapeutics stock soars to 52-week high of $24.4 - Investing.com
Cidara Therapeutics (NASDAQ:CDTX) versus Ginkgo Bioworks (NYSE:DNA) Financial Survey - Defense World
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Sees Large Increase in Short Interest - MarketBeat
Cidara Therapeutics (NASDAQ:CDTX) Coverage Initiated at Royal Bank of Canada - Defense World
RBC Capital Initiates Coverage of Cidara Therapeutics (CDTX) with Outperform Recommendation - MSN
Cidara Therapeutics (NASDAQ:CDTX) Now Covered by Analysts at Royal Bank of Canada - MarketBeat
Cidara achieves full enrolment in influenza prevention trial - Yahoo Finance
RA Capital Management L.P. Takes $7.56 Million Position in Cidara Therapeutics, Inc. (NASDAQ:CDTX) - MarketBeat
Cidara Therapeutics Completes Enrollment of Phase 2b - GlobeNewswire
Cidara Achieves Major Milestone: 5,000 Patients Enrolled in Game-Changing Universal Flu Prevention Trial - StockTitan
Cidara Therapeutics Inc Stock (CDTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cidara Therapeutics Inc Stock (CDTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Tari Leslie | CHIEF SCIENTIFIC OFFICER |
Sep 11 '24 |
Sale |
11.64 |
909 |
10,580 |
17,788 |
| Stein Jeffrey | President & CEO |
Jun 07 '24 |
Buy |
13.21 |
8,000 |
105,680 |
24,580 |
| Tari Leslie | CHIEF SCIENTIFIC OFFICER |
Mar 11 '24 |
Sale |
0.67 |
21,029 |
14,085 |
258,681 |
| Sandison Taylor | Chief Medical Officer |
Mar 11 '24 |
Sale |
0.67 |
20,662 |
13,839 |
347,095 |
| Ward Shane | COO & CLO |
Mar 11 '24 |
Sale |
0.67 |
20,473 |
13,713 |
198,770 |
| Shah Preetam | CFO & CBO |
Mar 11 '24 |
Sale |
0.67 |
18,931 |
12,680 |
227,210 |
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):